Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306366874> ?p ?o ?g. }
- W4306366874 endingPage "5022" @default.
- W4306366874 startingPage "5022" @default.
- W4306366874 abstract "The aim of this review is to highlight mechanisms of immunosuppression for each agent, along with pooled analyses of infectious complications from the available medical literature. Rituximab confers no increase in grade ≥3 infectious risks, except in the case of patients with advanced-stage non-Hodgkin lymphoma. Gemtuzumab ozogamicin links with high rates of grade ≥3 infections which, however, are comparable with historical cohorts. Pembrolizumab exhibits a favorable safety profile in terms of severe infections. Despite high rates of hypogammaglobulinemia (HGG) with blinatumomab, low-grade ≥3 infection rates were observed, especially in the post-reinduction therapy of relapsed B-acute lymphoblastic leukemia. Imatinib and nilotinib are generally devoid of severe infectious complications, but dasatinib may slightly increase the risk of opportunistic infections. Data on crizotinib and pan-Trk inhibitors entrectinib and larotrectinib are limited. CAR T-cell therapy with tisagenlecleucel is associated with grade ≥3 infections in children and is linked with HGG and the emergence of immune-related adverse events. Off-label therapies inotuzumab ozogamicin, brentuximab vedotin, and venetoclax demonstrate low rates of treatment-related grade ≥3 infections, while the addition of bortezomib to standard chemotherapy in T-cell malignancies seems to decrease the infection risk during induction. Prophylaxis, immune reconstitution, and vaccinations for each targeted agent are discussed, along with comparisons to adult studies." @default.
- W4306366874 created "2022-10-17" @default.
- W4306366874 creator A5023897674 @default.
- W4306366874 creator A5032935188 @default.
- W4306366874 creator A5033778704 @default.
- W4306366874 creator A5042603050 @default.
- W4306366874 creator A5079525798 @default.
- W4306366874 date "2022-10-14" @default.
- W4306366874 modified "2023-09-30" @default.
- W4306366874 title "Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas" @default.
- W4306366874 cites W1485169915 @default.
- W4306366874 cites W1590009046 @default.
- W4306366874 cites W1754303722 @default.
- W4306366874 cites W1976540144 @default.
- W4306366874 cites W1988779324 @default.
- W4306366874 cites W1988904395 @default.
- W4306366874 cites W1991789019 @default.
- W4306366874 cites W1993428519 @default.
- W4306366874 cites W1993649303 @default.
- W4306366874 cites W1994162484 @default.
- W4306366874 cites W1998569278 @default.
- W4306366874 cites W2013176883 @default.
- W4306366874 cites W2034690929 @default.
- W4306366874 cites W2036009499 @default.
- W4306366874 cites W2039983062 @default.
- W4306366874 cites W2049558499 @default.
- W4306366874 cites W2056545314 @default.
- W4306366874 cites W2059614461 @default.
- W4306366874 cites W2060244206 @default.
- W4306366874 cites W2060466778 @default.
- W4306366874 cites W2072900107 @default.
- W4306366874 cites W2075902150 @default.
- W4306366874 cites W2077362224 @default.
- W4306366874 cites W2078069330 @default.
- W4306366874 cites W2084452268 @default.
- W4306366874 cites W2084958083 @default.
- W4306366874 cites W2088217846 @default.
- W4306366874 cites W2090070060 @default.
- W4306366874 cites W2093353574 @default.
- W4306366874 cites W2093653074 @default.
- W4306366874 cites W2096336184 @default.
- W4306366874 cites W2099172974 @default.
- W4306366874 cites W2107419121 @default.
- W4306366874 cites W2107943299 @default.
- W4306366874 cites W2107968021 @default.
- W4306366874 cites W2112271707 @default.
- W4306366874 cites W2115623838 @default.
- W4306366874 cites W2116001192 @default.
- W4306366874 cites W2122677854 @default.
- W4306366874 cites W2123755151 @default.
- W4306366874 cites W2124658474 @default.
- W4306366874 cites W2127226843 @default.
- W4306366874 cites W2129702476 @default.
- W4306366874 cites W2136845772 @default.
- W4306366874 cites W2137149985 @default.
- W4306366874 cites W2144466728 @default.
- W4306366874 cites W2145016993 @default.
- W4306366874 cites W2148594538 @default.
- W4306366874 cites W2151296781 @default.
- W4306366874 cites W2159659043 @default.
- W4306366874 cites W2160026729 @default.
- W4306366874 cites W2164481024 @default.
- W4306366874 cites W2167126600 @default.
- W4306366874 cites W2167877833 @default.
- W4306366874 cites W2169923083 @default.
- W4306366874 cites W2186803779 @default.
- W4306366874 cites W2281010422 @default.
- W4306366874 cites W2314977550 @default.
- W4306366874 cites W2322792285 @default.
- W4306366874 cites W2384346244 @default.
- W4306366874 cites W2414802238 @default.
- W4306366874 cites W2439114453 @default.
- W4306366874 cites W2501477115 @default.
- W4306366874 cites W2529226476 @default.
- W4306366874 cites W2550019696 @default.
- W4306366874 cites W2579929646 @default.
- W4306366874 cites W2605949353 @default.
- W4306366874 cites W2606654718 @default.
- W4306366874 cites W2609398215 @default.
- W4306366874 cites W2609973112 @default.
- W4306366874 cites W2610068452 @default.
- W4306366874 cites W2614019261 @default.
- W4306366874 cites W2742652175 @default.
- W4306366874 cites W2783493696 @default.
- W4306366874 cites W2786511378 @default.
- W4306366874 cites W2786639886 @default.
- W4306366874 cites W2787301955 @default.
- W4306366874 cites W2788138754 @default.
- W4306366874 cites W2791994878 @default.
- W4306366874 cites W2793405459 @default.
- W4306366874 cites W2795040138 @default.
- W4306366874 cites W2800351065 @default.
- W4306366874 cites W2801040745 @default.
- W4306366874 cites W2806544610 @default.
- W4306366874 cites W2808879139 @default.
- W4306366874 cites W2809367512 @default.
- W4306366874 cites W2884311669 @default.
- W4306366874 cites W2886678686 @default.